These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 37408186)

  • 1. Impact of Combined Baricitinib and FTI Treatment on Adipogenesis in Hutchinson-Gilford Progeria Syndrome and Other Lipodystrophic Laminopathies.
    Hartinger R; Lederer EM; Schena E; Lattanzi G; Djabali K
    Cells; 2023 May; 12(10):. PubMed ID: 37408186
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Baricitinib, a JAK-STAT Inhibitor, Reduces the Cellular Toxicity of the Farnesyltransferase Inhibitor Lonafarnib in Progeria Cells.
    Arnold R; Vehns E; Randl H; Djabali K
    Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299092
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of Progerin Expression on Adipogenesis in Hutchinson-Gilford Progeria Skin-Derived Precursor Cells.
    Najdi F; Krüger P; Djabali K
    Cells; 2021 Jun; 10(7):. PubMed ID: 34202258
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of mitochondrial dysfunction in Hutchinson-Gilford progeria syndrome through use of stable isotope labeling with amino acids in cell culture.
    Rivera-Torres J; Acín-Perez R; Cabezas-Sánchez P; Osorio FG; Gonzalez-Gómez C; Megias D; Cámara C; López-Otín C; Enríquez JA; Luque-García JL; Andrés V
    J Proteomics; 2013 Oct; 91():466-77. PubMed ID: 23969228
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of MnTBAP and Baricitinib Treatment on Hutchinson-Gilford Progeria Fibroblasts.
    Vehns E; Arnold R; Djabali K
    Pharmaceuticals (Basel); 2022 Jul; 15(8):. PubMed ID: 36015093
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of JAK-STAT Signaling with Baricitinib Reduces Inflammation and Improves Cellular Homeostasis in Progeria Cells.
    Liu C; Arnold R; Henriques G; Djabali K
    Cells; 2019 Oct; 8(10):. PubMed ID: 31635416
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Presence and distribution of progerin in HGPS cells is ameliorated by drugs that impact on the mevalonate and mTOR pathways.
    Clements CS; Bikkul MU; Ofosu W; Eskiw C; Tree D; Makarov E; Kill IR; Bridger JM
    Biogerontology; 2019 Jun; 20(3):337-358. PubMed ID: 31041622
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intermittent treatment with farnesyltransferase inhibitor and sulforaphane improves cellular homeostasis in Hutchinson-Gilford progeria fibroblasts.
    Gabriel D; Shafry DD; Gordon LB; Djabali K
    Oncotarget; 2017 Sep; 8(39):64809-64826. PubMed ID: 29029393
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Naïve adult stem cells from patients with Hutchinson-Gilford progeria syndrome express low levels of progerin in vivo.
    Wenzel V; Roedl D; Gabriel D; Gordon LB; Herlyn M; Schneider R; Ring J; Djabali K
    Biol Open; 2012 Jun; 1(6):516-26. PubMed ID: 23213444
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hutchinson-Gilford Progeria Syndrome (Hgps) and Application of Gene Therapy Based Crispr/Cas Technology as A Promising Innovative Treatment Approach.
    Rajeev M; Ratan C; Krishnan K; Vijayan M
    Recent Pat Biotechnol; 2021; 15(4):266-285. PubMed ID: 34602042
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An overview of treatment strategies for Hutchinson-Gilford Progeria syndrome.
    Harhouri K; Frankel D; Bartoli C; Roll P; De Sandre-Giovannoli A; Lévy N
    Nucleus; 2018 Jan; 9(1):246-257. PubMed ID: 29619863
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cellular stress and AMPK activation as a common mechanism of action linking the effects of metformin and diverse compounds that alleviate accelerated aging defects in Hutchinson-Gilford progeria syndrome.
    Finley J
    Med Hypotheses; 2018 Sep; 118():151-162. PubMed ID: 30037605
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Status of treatment strategies for Hutchinson-Gilford progeria syndrome with a focus on prelamin: A posttranslational modification.
    Chen X; Yao H; Andrés V; Bergo MO; Kashif M
    Basic Clin Pharmacol Toxicol; 2022 Oct; 131(4):217-223. PubMed ID: 35790078
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hutchinson-Gilford progeria syndrome.
    Pollex RL; Hegele RA
    Clin Genet; 2004 Nov; 66(5):375-81. PubMed ID: 15479179
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emerging candidate treatment strategies for Hutchinson-Gilford progeria syndrome.
    Strandgren C; Revêchon G; Sola-Carvajal A; Eriksson M
    Biochem Soc Trans; 2017 Dec; 45(6):1279-1293. PubMed ID: 29127216
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sulforaphane enhances progerin clearance in Hutchinson-Gilford progeria fibroblasts.
    Gabriel D; Roedl D; Gordon LB; Djabali K
    Aging Cell; 2015 Feb; 14(1):78-91. PubMed ID: 25510262
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A farnesyltransferase inhibitor improves disease phenotypes in mice with a Hutchinson-Gilford progeria syndrome mutation.
    Yang SH; Meta M; Qiao X; Frost D; Bauch J; Coffinier C; Majumdar S; Bergo MO; Young SG; Fong LG
    J Clin Invest; 2006 Aug; 116(8):2115-21. PubMed ID: 16862216
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Truncated prelamin A expression in HGPS-like patients: a transcriptional study.
    Barthélémy F; Navarro C; Fayek R; Da Silva N; Roll P; Sigaudy S; Oshima J; Bonne G; Papadopoulou-Legbelou K; Evangeliou AE; Spilioti M; Lemerrer M; Wevers RA; Morava E; Robaglia-Schlupp A; Lévy N; Bartoli M; De Sandre-Giovannoli A
    Eur J Hum Genet; 2015 Aug; 23(8):1051-61. PubMed ID: 25649378
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Towards delineating the chain of events that cause premature senescence in the accelerated aging syndrome Hutchinson-Gilford progeria (HGPS).
    Dreesen O
    Biochem Soc Trans; 2020 Jun; 48(3):981-991. PubMed ID: 32539085
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.